Business
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an investigator-sponsored trial with onvansertib in chronic myelomonocytic leukemia (CMML) will be presented in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting. In this Phase 1 dose escalation trial (N=9), onvansertib
About this update from Cardiff Oncology, Inc.
[{"type":"image","alt":"Cardiff Oncology, Inc.","displaySize":"","headline":null,"caption":"Cardiff Oncology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/c3438e5d34725b0f8f9b8f7493032b71"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wD6rQtC_HUbA6JNQ3Eac3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c3438e5d34725b0f8f9b8f7493032b71","width":300,"height":89}},"lazy":false},{"type":"text","content":"SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an investigator-sponsored trial with onvansertib in chronic myelomonocytic leukemia (CMML) will be presented in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting.","length":442,"tagName":"p"},{"type":"text","content":"In this Phase 1 dose escalation trial (N=9), onvansertib as a monotherapy was shown to be relatively well-tolerated, and demonstrated preliminary efficacy in approximately 40% of patients, with one patient having an optimal marrow response at the 9 mg/m2 dose. These results, along with previously announced data from an investigator-sponsored trial in small cell lung cancer, validate onvansertib’s single agent activity in both hematologic and solid tumors. Cardiff Oncology is not currently planning to develop onvansertib for CMML.","length":535,"tagName":"p"},{"type":"text","content":"Poster Details:Title: Phase 1 clinical trial assessing the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in Relapsed/Refractory myeloproliferative chronic myelomonocytic leukemia (CMML)Session-Type: Poster Abstract SessionSpeaker: Mrinal Patnaik, MD, MBBS, Mayo Clinic, Rochester, MN, United StatesDate: Monday, December 8, 2025 at 6:00-8:00 PM ESTPart of Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III","length":462,"tagName":"p"},{"type":"text","content":"The abstract can be found on the ASH Annual Meeting website, https://submit.hematology.org/program/presentation/674309","length":118,"tagName":"p"},{"type":"text","content":"About Cardiff Oncology, Inc.Cardiff Oncology is a clinical-s...